ZYDUS LIFESCIENCES LTD.

NSE : ZYDUSLIFEBSE : 532321ISIN CODE : INE010B01027Industry : Pharmaceuticals & DrugsHouse : Cadila
BSE936.30-8.85 (-0.94 %)
PREV CLOSE ( ) 945.15
OPEN PRICE ( ) 956.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 71819
TODAY'S LOW / HIGH ( )933.65 956.55
52 WK LOW / HIGH ( )482.55 1031.3
NSE937.00-7.85 (-0.83 %)
PREV CLOSE( ) 944.85
OPEN PRICE ( ) 954.80
BID PRICE (QTY) 937.00 (9)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1376748
TODAY'S LOW / HIGH( ) 934.00 954.80
52 WK LOW / HIGH ( )484.95 1031.7
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 15-05 1995
Management Info
Pankaj R Patel - Chairman Sharvil P Patel - Managing Director
Registered Office

Address Zydus Corporate Park, Scheme No.63,Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,Sarkhej - Gandhinagar Highway,
Ahmedabad,
Gujarat-382481

Phone 079-71800000 / 48040000

Email dhavalsoni@zyduscadila.com

Website www.zyduscadila.com

Registrars Details
Link Intime India Pvt Ltd.
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I),Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura,Ahmedabad
Listing : BSE, NSE, MCX
NEWS
08Apr Zydus Lifesciences informs about compl
In accordance with regulation 74(5) of the DP Regulations and based on t..
28Mar USFDA completes inspection at Zydus Li
United States Food and Drug Administration (USFDA) has completed inspect..
28Mar Zydus Lifesciences informs about discl
Zydus Lifesciences has informed that it enclosed a disclosure in prescri..
26Mar Zydus Lifesciences climbs on getting U
Zydus Lifesciences is currently trading at Rs. 1020.35, up by 20.85 poin..
23Mar Zydus Lifesciences gets USFDA’s tentat
Zydus Lifesciences has received tentative approval from the United State..
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit450415292
Gross Profit 5743 20322
Operating Profit 805930028
Net Sales 2371387316
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
NGL Fine-Chem (BSE)
 2542.60 (12.29%)
M.Cap (Rs. in Cr)1570.82
Neuland Laboratories (BSE)
 7654.80 (1.79%)
M.Cap (Rs. in Cr)9821.02
Mankind Pharma (BSE)
 2397.40 (5.05%)
M.Cap (Rs. in Cr)96037.07
Sanofi India (BSE)
 8470.70 (0.89%)
M.Cap (Rs. in Cr)19508.55
Solara Active Pharma (BSE)
 474.10 (12.15%)
M.Cap (Rs. in Cr)1706.58
Shareholding Pattern
PROMOTERS 74.98%
MUTUAL FUNDS/UTI 6.71%
NON-INSTITUTION 6.66%
FI/BANKS/INSURANCE 5.74%
GOVERNMENT 0%
FII 0%
ATTENTION INVESTORSKYCIPO
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.